Genome wide DNA methylation profiling identifies specific epigenetic features in high-risk cutaneous squamous cell carcinoma.

Data de publicació: 20/12/2019

Autors de IIS La Fe

• David Hervás Marín

  Autor

• Onofre Sanmartin Jimenez

  Autor

• Juan Sandoval Del Amor

  Autor

Autors aliens a IIS La Fe

• Higgins F
• López-Guerrero JA
• Bañó MC
• Igual JC
• Quilis I

Grups d'Investigació

• Unidad de Biomarcadores y Medicina de Precisión (UBYMP)

  

  Leader

  Agustín Lahoz Rodríguez

Abstract

Cutaneous squamous cell carcinoma (cSCC) is the second most common skin cancer. Although most cSCCs have good prognosis, a subgroup of high-risk cSCC has a higher frequency of recurrence and mortality. Therefore, the identification of molecular risk factors associated with this aggressive subtype is of major interest. In this work we carried out a global-scale approach to investigate the DNA-methylation profile in patients at different stages, from premalignant actinic keratosis to low-risk invasive and high-risk non-metastatic and metastatic cSCC. The results showed massive non-sequential changes in DNA-methylome and identified a minimal methylation signature that discriminates between stages. Importantly, a direct comparison of low-risk and high-risk stages revealed epigenetic traits characteristic of high-risk tumours. Finally, a prognostic prediction model in cSCC patients identified a methylation signature able to predict the overall survival of patients. Thus, the analysis of DNA-methylation in cSCC revealed changes during the evolution of the disease through the different stages that can be of great value not only in the diagnosis but also in the prognosis of the disease.